(VIANEWS) – The NASDAQ opens in less than two hours and FibroGen‘s pre-market value is already 7.31% down.
FibroGen’s last close was $0.89, 96.55% below its 52-week high of $25.69.
The last session, NASDAQ ended with FibroGen (FGEN) falling 2.49% to $0.89. NASDAQ fell 0.56% to $15,011.35, after two consecutive sessions in a row of losses, on what was a somewhat negative trend exchanging session.
About FibroGen
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and Duchenne muscular dystrophy; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
Earnings Per Share
As for profitability, FibroGen has a trailing twelve months EPS of $-3.06.
Moving Average
FibroGen’s value is way above its 50-day moving average of $0.58 and way under its 200-day moving average of $6.96.
Earnings Before Interest, Taxes, Depreciation, and Amortization
FibroGen’s EBITDA is 1.6.
Sales Growth
FibroGen’s sales growth is 5.3% for the present quarter and 16.4% for the next.
More news about FibroGen (FGEN).
